Bank of America has re rated DNA and OSIP on the back of better than expected sales of NSCLC drug Tarceva . DNA has been given a target of $62 up a further 5Billion and OSIP target is $86 up about 2Billion market cap
Solbecs drug is shaping up as very (more?)effective against NSCLC .
www.forbes.com/markets/2005/04/12/0412automarketscan13.html?partner=yahoo&referrer=
